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INTRODUCTION
Dementia has been an important issue in many countries 
due to worldwide trend of population aging.1 In South Korea, 
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the number of patients with dementia has continuously in-
creased due to a very rapid rate of population aging.2 Accord-
ing to the National Institute of Dementia, 750,488 persons were 
estimated to have dementia (about 10.16% of people aged 65 
and over) in South Korea in 2019.3 Social cost per year per pa-
tient with dementia was estimated at 20,420,000 Korean Won 
(KW; 1 USD=1,206 KW as of 2020).3 Total public manage-
ment cost for patients with dementia was estimated at 15,300 
billion KW (i.e., 12,700 million USD).3 It has been predicted 
that cost for patients with dementia would increase to 3 mil-
lion by 2050 in South Korea.3 Accordingly, social cost will in-
crease rapidly.
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Objective   This study aimed to investigate treatment effects of combination therapy of memantine and acetylcholinesterase inhibitors 
(AchEIs) compared with AchEIs alone on behavioral and psychological symptoms of dementia (BPSD) in patients with moderate Al-
zheimer’s dementia (AD).
Methods   This was a 12-week, double-blind, randomized, placebo-controlled trial. A total of 148 patients with moderate AD participat-
ed in this study. Mini-Mental State Examination, Neuropsychiatric Inventory (NPI), Clinician’s Interview-Based Impression of Change 
plus caregiver input, Gottfries–Bråne–Steen Scale, and Zarit Burden Interview were used as assessment scales.
Results   There were no significant differences in age, sex, or education between AChEIs alone and combination groups. The combina-
tion group showed significantly more improvement of NPI-disinhibition score (0.76±2.15) than the AChEIs alone group (-0.14±1.71) af-
ter 12 weeks.
Conclusion   Our findings suggest that the combination therapy of memantine and AchEIs might be a beneficial option for reducing dis-
inhibition symptoms of patients with moderate AD compared with AchEIs alone. We believe that clinicians need to consider additional 
memantine treatment when patients with moderate AD complain disinhibition symptom. A larger clinical trial is needed to further deter-
mine the efficacy and advantages of such combination therapy of memantine and AchEIs for treating BPSD of patients with moderate AD.
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Social cost of dementia is closely associated with behav-
ioral and psychological symptoms of dementia (BPSD)4-6 be-
cause BPSD can increase caregiver distress and nursing home 
placement.4,7 Many clinicians and researchers have focused 
on alleviating BPSD such as insomnia, anxiety, aggression, 
agitation, delusion, hallucination, disinhibition, and wander-
ing.8 Trinh et al.9 have shown that the efficacy of acetylcholin-
esterase inhibitors (AchEIs) commonly used for cognitive 
symptom of Alzheimer’s dementia (AD) is insufficient for 
treating BPSD. Some studies have recommended low-dose 
antipsychotics (aripiprazole, olanzapine, risperidone, quetiap-
ine, and haloperidol) for treating agitation and aggression in 
patients with dementia.10,11 Selective serotonin reuptake in-
hibitors have also been used for reducing depression and agi-
tation.11,12 In addition, benzodiazepine and carbamazepine 
have been studied for treating BPSD, although common use 
of these medications is not recommended due to side effects 
and drug interactions.13,14 Up to date, consensus and guideline 
regarding medications for treating BPSD in patients with de-
mentia have not been established yet.
Memantine is an uncompetitive (channel blocking) N-
methyl-D-aspartate receptor antagonist. It was approved for 
treating moderate-to-severe AD by Food and Drug Adminis-
tration in 2003.8,15 Many researchers have studied the effect of 
memantine in patients with AD.16-18 Parsons et al.19 have shown 
that a combination therapy of memantine and AchEIs has 
complementary and synergistic effects. However, there is still 
not enough evidence to verify the effect of memantine for 
treating BPSD, though memantine has been one candidate 
medication for treating BPSD in patients with AD. 
In this study, we conducted a double-blind, randomized, 
placebo-controlled trial to investigate the effect of combina-
tion therapy of memantine and AchEIs compared with AchEIs 
alone for treating BPSD in patients with moderate AD.
METHODS
Study design
This was a 12-week, multi-center (six), prospective, double-
blind, randomized, placebo-controlled, parallel group trial. 
The trial was registered (registration number: IIT 16395T). 
The trial was initiated on Apr. 26, 2016. All visits were com-
pleted by Oct. 23, 2019. This study was approved by the Insti-
tutional Review Board of Inje University Ilsan Paik Hospital 
(2015-06-008), Soonchunhyang University Bucheon Hospital 
(2015-07-018), Gachon University Gil Medical Center, Myongji 
Hospital (MJH 2017-09-034), Gangdong Sacred Heart Hos-
pital (2018-08-006), and Korea University Ansan Hospital 
(2015AS0096). All subjects and their legal guardians (family 
members or caregivers) were informed of the study protocol. 
They provided written informed consent.
Subjects
A total of 148 older adults from Inje University Ilsan Paik 
Hospital (n=48; 32.4%), Soonchunhyang University Bucheon 
Hospital (n=34; 23.0%), Gachon University Gil Medical Cen-
ter (n=30; 20.3%), Myongji Hospital (n=27; 18.2%), Gangdong 
Sacred Heart Hospital (n=5; 3.4%), and Korea University An-
san Hospital (n=4; 2.7%) participated in this study. This study 
enrolled patients with AD who met the criteria for “major neu-
rocognitive disorder due to Alzheimer’s disease” proposed by 
the fifth version of the Diagnostic and Statistical Manual for 
Mental Disorders (DSM-5).20 We enrolled patients with mod-
erate AD considering the indication of memantine and the 
onset timing of BPSD.8
Subjects enrolled for this study met the following inclusion 
criteria: 1) aged over 60 years old, 2) scored 10–20 in Mini-
Mental State Examination (MMSE), 3) scored ≥11 in Neuro-
psychiatric Inventory (NPI), 4) took AchEIs for over six months, 
including donepezil, rivastigmine, and galantamine, 5) had 
unchanged AchEIs dosages for at least three months, 6) had 
caregiver who could provide reliable information and accom-
pany participants whenever visiting the hospital during the 
study period. During screening and diagnostic procedures, 
we applied the following patient exclusion criteria: 1) those 
who had experienced cerebrovascular diseases or traumatic 
brain diseases, 2) those who had alcohol or other substance 
use disorders, 3) those who had fatal or serious medical dis-
eases, and 4) those who had visual or hearing impairment at 
a level where assessments for studies including neuropsy-
chological tests and clinical scales were impossible. Geriatric 
psychiatrists certified by Korean Association for Geriatric 
Psychiatry were responsible for all screening and diagnostic 
procedures. 
Assessment
At baseline assessment, demographic data such as age, sex, 
and years of education were obtained. In addition, all partici-
pants and their caregivers used the following scales during the 
study period.
MMSE is a simple measure of cognitive function that has 
been used in clinical evaluation of patients with dementia.21 
Among various Korean versions of MMSE, we adopted the 
MMSE-KC version: MMSE in the Korean version of Consor-
tium to Establish a Registry for Alzheimer’s disease (CERAD) 
assessment packet.22 NPI was conducted to assess behavioral 
and psychiatric symptoms of dementia.23 NPI consisted of 12 
symptoms. Each symptom was scored according to its fre-
quency and severity.23 We used Korean version of NPI and ad-
opted the sum of composite scores (frequency x severity).24 
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This study also used Clinician’s Interview-Based Impression 
of Change plus caregiver input (CIBIC-Plus).25 CIBIC-Plus is 
a clinician rating scale that evaluates change in patients’ over-
all condition. Gottfries–Bråne–Steen Scale (GBS) focuses on 
the overall assessment of patients with dementia.26 GBS con-
sists of subscales regarding cognition, emotion, activities of 
daily living, and behavioral and psychological symptoms. We 
adopted GBS for caregiver interview. In addition, we adopted 
Zarit Burden Interview (ZBI) for interviewing caregivers of 
patients with dementia.27,28 ZBI has been widely used to assess 
caregiver burden related to dementia. 
Procedure
Subjects were randomized using a stratified block random-
ization method. Statisticians who were blinded to clinical in-
formation conducted a 1:1 ratio randomization using Statis-
tical Analysis System (SAS Institute Inc. Cary, NC, USA). All 
participants took memantine or placebo two times a day dur-
ing 12 weeks according to their randomized group allocation. 
Memantine and placebo had the same appearance. They were 
provided using blister packs. Participants in the combination 
group initially received 5 mg memantine per day. The dosage 
of memantine was then increased to 20 mg/day between 3 and 
8 weeks considering side effects. Medication adherence was 
monitored using pill count method referring to remaining 
empty blister packs. Antidepressants/benzodiazepines/cog-
nitive enhancers–unchanged medication dosages for at least 
three months–and medications for physical illness were per-
mitted during the study period. However, the following medi-
cations were not allowed to be co-administered until the end 
of this study: amantadine, ketamine, detromethorphan, phe-
nytoin, cimetidine, ranitidine, procainamide, quinidine, qui-
nine, and nicotine. Figure 1 shows the schedule for assessments 
including effectiveness and safety.
Statistical analysis
Descriptive statistics were calculated for all variables. Per-
centages were calculated for categorical variables while means 
and standard deviations were calculated for continuous vari-
ables. Independent t-test was used for analyzing differences in 
baseline characteristics and changes of scale scores between 
AChEIs alone and combination groups. The last observation 
carried forward (LOCF) approach was adopted to handle 
missing data. 
A p-value of <0.05 was considered statistically significant. 
All statistical analyses were performed using R version 3.6.2 
(The R Foundation for Statistical Computing Platform, Vien-
na, Austria).
RESULTS
Table 1 shows basic characteristics of the AChEIs alone and 
combination groups. The mean age of subjects was 78.18± 
6.85 years in the AChEIs alone group and 78.23±6.59 years in 
Baseline: medical history/physical examination, vital sign, 
concomitant medications, demographic data,
MMSE, NPI, CIBIC-Plus, GBS, ZBI
Week 4: vital sign, concomitant medications, adverse events,
NPI, CIBIC-Plus
Week 2: vital sign, concomitant medications, adverse events,
MMSE, NPI, CIBIC-Plus, GBS, ZBI
Figure 1. The schedule for assessments. MMSE: Mini-Mental State 
Examination, NPI: Neuropsychiatric Inventory, CIBIC-Plus: Clinician’s 
Interview-Based Impression of Change plus caregiver input, GBS: 
Gottfries– Bråne–Steen Scale, ZBI: Zarit Burden Interview.
Table 1. Baseline characteristics of participants in AchEIs alone and combination groups
Total (N=148) AchEIs alone (N=74) Combination (N=74) t-value p-value*
Age (years) 78.20±6.69 78.18±6.85 78.23±6.59 -0.05 0.963
Sex (male/female) 39/109 18/56 21/53 0.56 0.579
Education (years) 6.95±5.07 6.69±5.11 7.22±5.05 -0.63 0.527
MMSE 15.61±3.41 15.71±3.35 15.51±3.50 0.36 0.717
NPI 24.59±16.43 24.73±15.31 24.45±17.60 0.10 0.920
CIBIC-Plus 4.13±0.69 4.10±0.68 4.15±0.71 -0.47 0.641
GBS 43.12±24.04 43.44±24.30 42.79±23.94 0.16 0.872
ZBI 34.59±17.59 36.74±17.15 32.40±17.88 1.49 0.138
*p values were calculated using chi-square test and independent t-test. MMSE: Mini-Mental State Examination, NPI: Neuropsychiatric Inven-
tory, CIBIC-Plus: Clinician’s Interview-Based Impression of Change plus caregiver input, GBS: Gottfries– Bråne–Steen Scale, ZBI: Zarit Burden 
Interview
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the combination group. More females than males participat-
ed in both groups. There were no significant differences in 
age, sex, or education between AChEIs alone and combina-
tion groups. No one specifically complained about the symp-
toms of side effects, and no one stopped taking drugs because 
of drug adverse events.
Changes of scale scores in AChEIs alone and combination 
groups during the follow-up period are shown in Tables 2 and 
3. The combination group showed significantly more im-
provement of NPI-disinhibition score (0.76±2.15) than the 
AChEIs alone group (-0.14±1.71) after 12 weeks, although 
there was no significant difference in this score between the 
two groups at week 4. CIBIC-Plus change scores did not dif-
fer significantly between the two groups at week 4 or week 12 
(Table 4). 
DISCUSSION
South Korea has national health insurance system which 
covers all health services of approximately 50 million Kore-
ans.29 Accordingly, almost all medications are controlled by 
criteria for National Health Insurance coverage. Recommend-
ed National Health Insurance criterion for memantine pre-
scription is MMSE ≤20 (and Clinical Dementia Rating 2–3 
or Global Deterioration Scale 4–7). According to 2019 statis-
tics of National Institute of Dementia, the target population of 
memantine use in South Korea was estimated to be approxi-
mately 350,000.3 There were about 220,000 patients with mod-
erate degree of AD in that report, consistent with the inclusion 
criteria of our study.3 Although statistics data are limited, the 
prevalence of BPSD is relatively high (50–80%) in patients with 
dementia.30-32 Therefore, many older adults can get help if the 
effect of memantine for treating BPSD is confirmed.
Previous double-blind, randomized, placebo-controlled 
studies have reported the effect of combination therapy of 
memantine and AchEIs. Tariot et al.33 have enrolled 404 pa-
tients with AD (MMSE of 5 to 14) and found that patients in 
the memantine group have significantly better outcomes than 
those in placebo group based on measures of cognition, activ-
ities of daily living, global outcome, and behavior. Grossberg 
et al.34 have also reported that patients with AD (MMSE of 3 
to 14) in the memantine group have cognitive, global, and be-
havioral benefits. However, some studies on AD patients with 
relatively less severe stages have shown different results. Por-
steinsson et al.35 have included 433 AD patients with MMSE of 
10 to 22 and found that those in the memantine group do not 
show an advantage over those in the placebo group regard-
ing cognition, activities of daily living, global outcome, or be-
havior. Similarly, Choi et al.36 have reported that the combina-
tion therapy of memantine plus rivastigmine patch does not 
show an advantage over rivastigmine patch monotherapy in 
patients with AD (50 to 90 years old with MMSE of 10 to 20). 
Our study found that patients with moderate AD treated with 
the combination therapy of memantine and AchEIs had sig-
nificant improvement in disinhibition symptoms of BPSD 
compared with those who treated with AchEIs alone. Con-
sidering that previous studies did not validate an advantage of 
combination therapy of memantine plus AchEIs in patients 
with moderate AD, the result of our study might be used as a 
reference when treating patients with moderate AD.
Causes and pathophysiology of BPSD are incompletely un-
derstood.37 Likewise, pathophysiology, phenomenology, main 
clinical correlates, and long-term evolution of disinhibition 
symptom in dementia remain unclear.38 Accordingly, it might 
be difficult to elucidate the association between memantine 
and improvement of disinhibition symptoms. Povysheva and 
Johnson have suggested that memantine can affect excitation-
inhibition balance in the prefrontal cortex.39 Araki et al.40 have 
reported that combination treatment of memantine and do-
nepezil can inhibit the reduction of cerebral blood flow in the 
prefrontal area of a patient with AD. Considering that prefron-
tal cortex is one of the regions associated with disinhibition 
symptom, these previous studies might help explain results 
of our analysis.41
The question of NPI-disinhibition item is “Does the patient 
seem to act impulsively, for example, talking to strangers as if 
he/she knows them, or saying things that may hurt people’s 
feelings?”23 Lyketsos et al.42 have shown that the prevalence 
of NPI-disinhibition item is 12.7% in patients with dementia. 
Kaufer et al.43 have also reported a prevalence of 10–13% of 
NPI-disinhibition item in patients with moderate to severe 
dementia. In addition, Starkstein et al.38 have investigated the 
prevalence of abnormal behaviors in patients with dementia 
and reported that inappropriate social behavior is one of the 
most frequent symptoms. Therefore, clinicians may often en-
counter AD patients with disinhibition symptoms. The use of 
additional memantine might be considered each time.
Our findings suggest that the combination therapy of me-
mantine and AchEIs might be a beneficial option for reduc-
ing disinhibition symptoms of patients with moderate AD 
compared with AchEIs alone. That is, combination therapy of 
memantine and AchEIs may be considered when disinhibition 
symptoms of patients with moderate AD are encountered or 
when disinhibition symptoms are unresponsive to AchEIs 
only. An additional implication of this study is that it suggests 
the possibility of using memantine combination therapy for 
patients with moderate AD for treating BPSD. A larger clini-
cal trial is needed to further determine the efficacy and ad-
vantages of such combination therapy of memantine and 
AchEIs for treating BPSD of patients with moderate AD. 
HC Youn et al. 
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However, this study has some limitations. First, the sample 
size of this study was relatively small and most of our partici-
pants were females, thus limiting the generalizability of our 
results. Second, this study adopted only the MMSE score as 
an inclusion criterion for moderate AD. We believe that a 
more complex neuropsychiatric battery such as CERAD is 
needed for more appropriate classification. Third, our study 
analyzed the effect of combination therapy of memantine and 
AchEIs in patients with moderate AD. Further studies includ-
ing other AD groups with various severity stages are needed 
to provide more informative results. Fourth, the follow-up pe-
riod of this study was 12 weeks. Considering that patients tak-
ing memantine and AchEIs tend to maintain their medications 
for a long time, a longer follow-up period may be necessary. 
Finally, this study did not match kinds or doses of AchEIs. In 
addition, we also did not control kinds or doses of other drugs 
such as antidepressants, antipsychotics, and medications for 
physical illness. More controlled studies that address this issue 
are needed to verify the effect of such memantine combina-
tion therapy more clearly.
This study conducted a double-blind, randomized, placebo-
controlled trial to investigate the effect of combination thera-
py of memantine and AchEIs compared with AchEIs alone in 
patients with moderate AD. After 12 weeks of follow-up peri-
od, patients in the combination group showed an advantage 
over those in the AChEIs alone group for NPI-disinhibition 
items. We believe that clinicians may consider additional me-
mantine treatment when patients with moderate AD com-
plain disinhibition symptoms. Further larger clinical trials are 
needed to verify and determine advantages of such combina-
tion therapy of memantine and AchEIs for treating BPSD of 
patients with moderate AD.
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